Abstracto

Emerging therapeutic strategies for myelodysplastic syndromes: novel targets and approaches

Charles Eliot*

Myelodysplastic syndromes (MDS) are a group of hematological disorders characterized by abnormal blood cell production in the bone marrow. While current treatment options for MDS include chemotherapy, immunomodulatory agents, and stem cell transplantation, there is a need for novel therapeutic approaches that target the underlying molecular mechanisms of the disease. In this mini review, we will discuss emerging therapeutic strategies for MDS, including epigenetic modifiers, immune checkpoint inhibitors, and targeted therapies, and their potential impact on patient outcomes.